Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients


In the Clinical/Scientific Note, “Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients,” by M. van der Zwan et al.,¹ the final sentence under the “Study Design” subheading of the Methods section should read “Alemtuzumab was administered as a single dose of 30 mg subcutaneously and rATG in a dose of 4 mg/kg.” The publisher and authors regret the error.

Reference
Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients

Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000882

This information is current as of August 7, 2020